Modern biomedicine has achieved extraordinary resolution in observing biological components. Genes can be sequenced, proteins quantified, pathways mapped, and biomarkers tracked with remarkable precision. Yet across cancer, immunotherapy, chronic inflammatory disorders, and metabolic disease, durable therapeutic control remains fragile. The same intervention often yields divergent outcomes across patients and across time, with responses emerging and dissolving, resistance developing, and remission giving way to relapse. This recurring pattern suggests that the central limitation may not lie in the sophistication of available tools, but in the conceptual layer through which living systems are interpreted. Contemporary medicine is fundamentally target driven. It isolates molecular abnormalities and designs interventions to correct them. While indispensable, this paradigm implicitly assumes that governing components equates to governing systems. Living biology repeatedly violates this assumption. Biological systems adapt, reorganize, compensate, and reconfigure themselves under therapeutic pressure. This white paper advances the view that living systems are more coherently understood as occupying biological states rather than merely containing biological targets. Disease progression, immune dysfunction, therapeutic resistance, and recovery are framed as movements within a biological state space, rather than as isolated molecular events. On this basis, the paper argues that medicine must evolve from intervention centric thinking toward state centric thinking, shifting away from striking faults and toward interpreting and navigating biological configurations. This reframing establishes the intellectual foundations for a control level view of living medicine, with implications across immunotherapy, nanomedicine, diagnostics, and artificial intelligence in healthcare.
Sameer K. Varma (Thu,) studied this question.